Aktienanalyse zu Propanc Biopharma Inc (PPCB)PPCBPropanc Biopharma Inc

Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1. It operates in the Healthcare sector.

Propanc Biopharma Inc (PPCB) is not a good buy right now. The current price is $1.75, which is significantly down 98.78% year-to-date and 99.22% over the past year. The RSI is at 27.15, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the company's negative net income, which reached -$63,603,336 in Q3 2025, indicating ongoing financial struggles.